Can dysplasia surveillance be better targeted in ulcerative colitis by using faecal calprotectin?

References

• Nieminen U, Jussila A, Nordling S, et al. Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case–control observational study based on registry data. Int J Cancer. 2014;134(1):189–196.
   PubMed Web of Science ®Google Scholar
• Jess T, Rungoe C, Peyrin–Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10(6):639–645.
   PubMed Web of Science ®Google Scholar
• Kim ER, Chang DK. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. World J Gastroenterol. 2014;20(29):9872–9881.
   PubMed Web of Science ®Google Scholar
• Lopez A, Pouillon L, Beaugerie L, et al. Colorectal cancer prevention in patients with ulcerative colitis. Best Pract Res Clin Gastroenterol. 2018;32–33:103–109.
   PubMed Web of Science ®Google Scholar
• Manninen P, Karvonen A, Laukkarinen J, et al. Colorectal cancer and cholangiocarcinoma in patients with primary sclerosing cholangitis and inflammatory bowel disease. Scand J Gastroenterol. 2015;50(4):423–428.
   PubMed Web of Science ®Google Scholar
• Keller D, Windsor A, Cohen R, et al. Colorectal cancer in inflammatory bowel disease: review of the evidence. Tech Coloproctol. 2019;23(1):3–13.
   PubMed Web of Science ®Google Scholar
• Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526–535.
   PubMed Web of Science ®Google Scholar
• Bernstein C, Nugent Z, Blanchard J. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol. 2011;106(4):731–736.
   PubMed Web of Science ®Google Scholar
• Jess T, Loftus EJ, Velayos F, et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case–control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol. 2007;102(4):829–836.
   PubMed Web of Science ®Google Scholar
• Rutter M, Saunders B, Wilkinson K, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130(4):1030–1038.
   PubMed Web of Science ®Google Scholar
• Magro F, Gionchetti P, Eliakim R, European Crohn’s and Colitis Organisation [ECCO], et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649–670.
   PubMed Web of Science ®Google Scholar
• Manninen P, Karvonen A, Huhtala H, et al. The risk of colorectal cancer in patients with inflammatory bowel diseases in Finland: a follow-up of 20 years. J Crohn's Colitis. 2013;7:551–557.
   Google Scholar
• Jess T, Simonsen J, Jørgensen K, et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143(2):375–381.
   PubMed Web of Science ®Google Scholar
• Jussila A, Virta LJ, Kautiainen H, et al. Increasing incidence of inflammatory bowel diseases between 2000 and 2007: a nationwide register study in Finland. Inflamm Bowel Dis. 2012;18(3):555–561.
   PubMed Web of Science ®Google Scholar
• Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015;50(8):942–951.
   PubMed Web of Science ®Google Scholar
• Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119(1):15–22.
   PubMed Web of Science ®Google Scholar
• Puolanne A, Kolho K, Alfthan H, et al. Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease. Eur J Clin Invest. 2016;46(10):825–832.
   PubMedGoogle Scholar
• Molodecky N, Soon I, Rabi D, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54.
   PubMed Web of Science ®Google Scholar
• Jussila A, Virta L, Salomaa V, et al. High and increasing prevalence of inflammatory bowel disease in Finland with a clear North–South difference. J Crohn's Colitis. 2013;7:256–262.
   Google Scholar
• Manninen P, Karvonen A, Huhtala H, et al. The epidemiology of inflammatory bowel diseases in Finland. Scand J Gastroenterol. 2010;45(9):1063–1067.
   PubMed Web of Science ®Google Scholar
• Kolho K, Alfthan H. Concentration of fecal calprotectin in 11,255 children aged 0–18 years. Scand J Gastroenterol. 2020;55(9):1024–1027.
   PubMed Web of Science ®Google Scholar
• Gupta R, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133(4):1099–1105.
   PubMed Web of Science ®Google Scholar
• Langholz E. Current trends in inflammatory bowel disease: the natural history. Ther Adv Gastroenterol. 2010;3(2):77–86.
   PubMedGoogle Scholar
• Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107(1):3–11.
   PubMed Web of Science ®Google Scholar
• Burisch J, Pedersen N, Čuković-Čavka S, EpiCom-group, et al. East–west gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut. 2014;63(4):588–597.
   PubMed Web of Science ®Google Scholar
• Kolehmainen S, Lepistö A, Färkkilä M. Impact of anti-TNF-alpha therapy on colectomy rate and indications for colectomy in ulcerative colitis: comparison of two patient cohorts from 2005 to 2007 and from 2014 to 2016. Scand J Gastroenterol. 2019;54(6):707–711.
   PubMed Web of Science ®Google Scholar
• Kristinsson J, Røseth A, Fagerhol M, et al. Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum. 1998;41(3):316–321.
   PubMed Web of Science ®Google Scholar
• Lehmann F, Trapani F, Fueglistaler I, et al. Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma. WJG 2014;20(17):4994–4999.
   PubMed Web of Science ®Google Scholar
• Kronborg O. Colon polyps and cancer. Endoscopy. 2000;32(2):124–130.
   PubMedGoogle Scholar
• Tøn H, Brandsnes Ø, Dale S, et al. Improved assay for fecal calprotectin. Clin Chim Acta. 2000;292(1–2):41–54.
   PubMedGoogle Scholar
• Sipponen T, Kärkkäinen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment Pharmacol Ther. 2008;28(10):1221–1229.
   PubMed Web of Science ®Google Scholar
• D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218–2224.
   PubMed Web of Science ®Google Scholar
• Broomé U, Löfberg R, Veress B, et al. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology. 1995;22(5):1404–1408.
   PubMed Web of Science ®Google Scholar